Bay Street News

Denali Therapeutics Announces First Patient Dosed in Phase 1b Study of DNL747 for Alzheimer’s Disease

February 15, 2019
- NASDAQ Companies
  0
ShareTweet
ShareTweet
» View More News for February 15, 2019

Tweets by baystnews

© 2020 BayStNews.com - All Rights Reserved
  • Home
  • TSX News
  • TSX Venture News
  • NASDAQ Companies
  • NYSE Companies
  • Canadian Stock Exchange News
  • Pink Sheets News
  • OTCBB News
Contact Us

We're not around right now. But you can send us an email and we'll get back to you, asap.

Not readable? Change text. captcha txt

Start typing and press Enter to search